Kestra Advisory Services’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,940
Closed -$14.9K 3359
2025
Q4
$14.9K Sell
2,940
-1,550
-35% -$16.9K ﹤0.01% 4529
2025
Q3
$46.3K Buy
4,490
+201
+5% +$1.87K ﹤0.01% 2862
2025
Q2
$36.1K Buy
4,289
+138
+3% +$1.29K ﹤0.01% 2784
2025
Q1
$38.6K Buy
4,151
+57
+1% +$1.09K ﹤0.01% 2663
2024
Q4
$92.1K Sell
4,094
-171
-4% -$5.4K ﹤0.01% 2578
2024
Q3
$160K Sell
4,265
-731
-15% -$28.1K ﹤0.01% 2415
2024
Q2
$187K Buy
4,996
+31
+0.6% +$1.13K ﹤0.01% 2426
2024
Q1
$167K Buy
4,965
+345
+7% +$12.5K ﹤0.01% 2314
2023
Q4
$184K Buy
4,620
+335
+8% +$11.8K ﹤0.01% 2125
2023
Q3
$136K Buy
4,285
+2,233
+109% +$84.4K ﹤0.01% 1988
2023
Q2
$68.3K Buy
2,052
+900
+78% +$34.4K ﹤0.01% 2028
2023
Q1
$51.2K Buy
+1,152
New +$92.3K ﹤0.01% 1992
2022
Q3
Sell
-346
Closed -$58K 2128
2022
Q2
$58K Buy
346
+13
+4% +$1.98K ﹤0.01% 2029
2022
Q1
$62K Buy
+333
New +$69K ﹤0.01% 1955

Other funds holding CODX

Kestra Advisory Services's CODX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 2,940 shares — an estimated $14.9K sold.

Kestra Advisory Services first reported a position in CODX in Q1 2022 and held it in 14 quarters. The position peaked at $187K in Q2 2024. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 2,940 Co-Diagnostics shares in Q1 2026, an estimated $14.9K.
  • Kestra Advisory Services first reported a position in Co-Diagnostics in Q1 2022 and held it in 14 quarters.
  • Kestra Advisory Services's Co-Diagnostics position peaked at $187K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.